Financials data is unavailable for this security.
View more
Year on year Tibet Rhodiola Pharmaceutical Holding Co grew revenues 22.69% from 2.55bn to 3.13bn while net income improved 116.56% from 369.84m to 800.91m.
| Gross margin | 93.55% |
|---|---|
| Net profit margin | 28.56% |
| Operating margin | 31.82% |
| Return on assets | 16.43% |
|---|---|
| Return on equity | 22.83% |
| Return on investment | 22.82% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Tibet Rhodiola Pharmaceutical Holding Co fell by 245.11m. However, the company earned 1.06bn from its operations for a Cash Flow Margin of 33.93%. In addition the company used 831.88m on investing activities and also paid 483.69m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 11.76 |
|---|---|
| Tangible book value per share | 11.14 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.80 |
|---|---|
| Quick ratio | 2.71 |
| Total debt/total equity | 0.1974 |
|---|---|
| Total debt/total capital | 0.1636 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 159.92% and 116.80%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
| Div yield(5 year avg) | 2.15% |
|---|---|
| Div growth rate (5 year) | 48.97% |
| Payout ratio (TTM) | 59.70% |
| EPS growth(5 years) | 30.38 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 31.00 |
More ▼
